These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26068980)

  • 1. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
    Vassella E; Langsch S; Dettmer MS; Schlup C; Neuenschwander M; Frattini M; Gugger M; Schäfer SC
    Oncotarget; 2015 Sep; 6(27):23905-16. PubMed ID: 26068980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.
    Tochigi N; Dacic S; Nikiforova M; Cieply KM; Yousem SA
    Am J Clin Pathol; 2011 May; 135(5):783-9. PubMed ID: 21502435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
    Kang SM; Kang HJ; Shin JH; Kim H; Shin DH; Kim SK; Kim JH; Chung KY; Kim SK; Chang J
    Cancer; 2007 Feb; 109(3):581-7. PubMed ID: 17186532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
    Shu C; Cheng H; Wang A; Mansukhani MM; Powell CA; Halmos B; Borczuk AC
    Mod Pathol; 2013 Feb; 26(2):239-46. PubMed ID: 22996376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
    Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
    Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
    Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.
    Tseng LH; De Marchi F; Pallavajjalla A; Rodriguez E; Xian R; Belchis D; Gocke CD; Eshleman JR; Illei P; Lin MT
    Am J Clin Pathol; 2019 Oct; 152(5):570-581. PubMed ID: 31264684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
    Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi T; Taira T; Ono A; Maniwa T; Takahashi S; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Ohde Y; Yamamoto N
    BMC Cancer; 2014 Oct; 14():786. PubMed ID: 25348872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
    Jia XL; Chen G
    Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.